A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539 44. 113. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbid- ity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. 114. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of pa- tients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441 6. 115. Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysi- ologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Indian Heart J. 1996;48:133 7. 116. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871 8. 117. Domanovits H, Laske H, Stark G, et al. Adenosine for the manage- ment of patients with tachycardias-a new protocol. Eur Heart J. 1994;15:589 93. 118. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660 8. 119. Steinwender C, H nig S, Kypta A, et al. Pre-injection of magnesium sul- fate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter. Int J Cardiol. 2010;141:260 5. 120. Tercius AJ, Kluger J, Coleman CI, et al. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2007;30:1331 5. 121. P rez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after cath- eter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta- analysis. Circ Arrhythm Electrophysiol. 2009;2:393 401. 